{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AAT-placebo&page=2",
    "query": {
      "intervention": "AAT-placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AAT-placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T17:01:32.894Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03114020",
      "title": "Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Emphysema",
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Hyaluronic Acid Inhalation Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Inhalation Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gerard Turino",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 27,
      "start_date": "2017-03-22",
      "completion_date": "2019-11-12",
      "has_results": false,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-09-29T17:01:32.894Z",
      "location_count": 5,
      "location_summary": "Miami, Florida • Fayetteville, New York • Charleston, South Carolina + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Fayetteville",
          "state": "New York"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03114020"
    },
    {
      "nct_id": "NCT05856331",
      "title": "Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency",
        "Emphysema"
      ],
      "interventions": [
        {
          "name": "SAR447537",
          "type": "DRUG"
        },
        {
          "name": "Zemaira",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 99,
      "start_date": "2023-10-12",
      "completion_date": "2025-08-06",
      "has_results": false,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-09-29T17:01:32.894Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05856331"
    },
    {
      "nct_id": "NCT04764448",
      "title": "A Study of Belcesiran in Patients With AATLD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Belcesiran",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2021-02-12",
      "completion_date": "2024-05-29",
      "has_results": true,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-09-29T17:01:32.894Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Gainesville, Florida • Charleston, South Carolina",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04764448"
    },
    {
      "nct_id": "NCT01731691",
      "title": "Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Disease"
      ],
      "interventions": [
        {
          "name": "α1 Proteinase Inhibitor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Institute for Human Genetics and Biochemistry",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-04",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2020-08-31",
      "last_synced_at": "2026-09-29T17:01:32.894Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01731691"
    },
    {
      "nct_id": "NCT01379469",
      "title": "Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha-1-antitrypsin Deficiency",
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Drug-Carbamazepine (Tegretol XR)",
          "type": "DRUG"
        },
        {
          "name": "Carbamazepine (Tegretol XR) Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "14 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-01",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-09-29T17:01:32.894Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01379469"
    },
    {
      "nct_id": "NCT03945292",
      "title": "Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Fazisiran Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Arrowhead Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-08-07",
      "completion_date": "2023-09-18",
      "has_results": true,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-09-29T17:01:32.894Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03945292"
    },
    {
      "nct_id": "NCT00261833",
      "title": "Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alpha1-proteinase Inhibitor Deficiency",
        "Emphysema"
      ],
      "interventions": [
        {
          "name": "Alpha1-proteinase inhibitor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 180,
      "start_date": "2006-03",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2015-01-19",
      "last_synced_at": "2026-09-29T17:01:32.894Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Miami, Florida • Hershey, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00261833"
    },
    {
      "nct_id": "NCT01684410",
      "title": "Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Alpha-1 HC 100 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alpha-1 HC 200 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-08",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2016-02-08",
      "last_synced_at": "2026-09-29T17:01:32.894Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01684410"
    },
    {
      "nct_id": "NCT03636347",
      "title": "A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency",
        "Emphysema",
        "COPD"
      ],
      "interventions": [
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Alvelestat oral tablet - dose 1",
          "type": "DRUG"
        },
        {
          "name": "Alvelestat oral tablet - dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mereo BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 99,
      "start_date": "2018-10-29",
      "completion_date": "2022-03-30",
      "has_results": false,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-09-29T17:01:32.894Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03636347"
    },
    {
      "nct_id": "NCT06165341",
      "title": "Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alpha1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Fazirsiran Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2024-03-01",
      "completion_date": "2028-08-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-09-29T17:01:32.894Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06165341"
    }
  ]
}